AbbVie (NYSE:ABBV) Stock Falls 1% – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s share price dropped 1% on Tuesday. The stock traded as low as $261.52 and last traded at $263.5410. Approximately 3,946,828 shares were traded during trading, a decline of 39% from the average session volume of 6,468,157 shares. The stock had previously closed at $266.28.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 2 eczema data: AbbVie reported that all three dosing regimens of experimental IL-13 antibody zumilokibart significantly improved EASI-75 responses versus placebo in moderate-to-severe atopic dermatitis. The company selected the mid-dose regimen for Phase 3, strengthening its immunology pipeline and potential successor products. AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study
• Positive Sentiment: New growth opportunities: Detailed Phase 1 data for weight-management candidate ABBV-295 showed favorable tolerability, meaningful weight reduction and an approximately 11- to 12-day half-life, supporting progression into Phase 2 and potentially less-frequent dosing. AbbVie Presents Detailed Phase 1 Data for ABBV-295
• Positive Sentiment: Regulatory and analyst support: FDA approval of once-daily Parkinson’s treatment Juvmo expands AbbVie’s neurology portfolio and could address a sizable market. Bank of America also raised its AbbVie price target, citing growth and pipeline strength. AbbVie Wins FDA Nod for New Parkinson’s Disease Drug Juvmo
• Positive Sentiment: AbbVie’s broad dermatology presentation, AI collaboration with Valkai and early-stage trial progress add further evidence of ongoing pipeline investment.
• Neutral Sentiment: AbbVie will release third-quarter 2026 results before the market opens on October 30, giving investors a near-term catalyst for revenue, earnings and guidance updates. AbbVie to Host Third-Quarter 2026 Earnings Conference Call
• Negative Sentiment: ABBV is trading close to its 52-week high with a reported P/E ratio above 70, leaving less room for disappointment. The stock also decreased after the Juvmo approval, suggesting investors may be focused on launch execution, commercialization costs and whether the new drug can offset future patent-cliff concerns.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ABBV shares. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and upped their price objective for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. HSBC upped their price target on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Wells Fargo & Company lifted their price objective on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $225.00 price objective (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $272.66.

AbbVie Stock Performance

The company has a market cap of $462.36 billion, a P/E ratio of 73.95, a P/E/G ratio of 1.19 and a beta of 0.29. The firm’s fifty day moving average is $257.73 and its two-hundred day moving average is $234.11.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Institutional Trading of AbbVie

Hedge funds have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Capital Research Global Investors increased its position in AbbVie by 0.7% in the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after purchasing an additional 177,370 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Franklin Resources Inc. raised its stake in AbbVie by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock valued at $3,400,274,000 after purchasing an additional 330,104 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in AbbVie by 9.7% during the fourth quarter. Bank of New York Mellon Corp now owns 13,499,351 shares of the company’s stock valued at $3,084,467,000 after purchasing an additional 1,197,432 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.